New England Consortium

Dana-Farber/Boston Children's is an international leader in improving treatment and quality of life for children affected by sickle cell disease. We treat sickle cell anemia (HbSS), sickle cell with hemoglobin C disease (HbSC), hemoglobin S-beta-thalassemia (HbS?0 and Hb?+ thalassemia), and less common compound forms, including HbSD, HbSO and HbSE. Through our Sickle Cell Disease Program, children have access to world-renown pediatric hematologists, top-rated nursing care, and the latest treatment options including hydroxyurea and stem cell transplantation. We are also one of the few centers in the nation using a new type of technology, called PreciseType, to precisely match blood donors to sickle cell patients who need blood transfusion.

Dana-Farber/Boston Children's treats all primary liver tumors occurring in children and young adults. The two most common types of liver tumors are hepatoblastoma and hepatocellular carcinoma. We care for both newly diagnosed liver cancer and for children with relapsed disease. We have some of the most experienced pediatric liver cancer oncologists and surgeons in the world, as well as internationally recognized pediatric subspecialists who use sophisticated technology and therapies to maximize outcomes for our patients.